Ra Capital Management, L.P. Sells 53,345 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 53,345 shares of the firm’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $28.01, for a total value of $1,494,193.45. Following the completion of the transaction, the director directly owned 1,271,001 shares in the company, valued at $35,600,738.01. This trade represents a 4.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, October 27th, Ra Capital Management, L.P. sold 90,941 shares of Vor Biopharma stock. The shares were sold at an average price of $28.12, for a total value of $2,557,260.92.
• On Thursday, October 23rd, Ra Capital Management, L.P. sold 76,880 shares of Vor Biopharma stock. The shares were sold at an average price of $28.01, for a total value of $2,153,408.80.
• On Tuesday, October 21st, Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma stock. The shares were sold at an average price of $28.11, for a total value of $703,508.97.
• On Monday, October 20th, Ra Capital Management, L.P. sold 92,023 shares of Vor Biopharma stock. The shares were sold at an average price of $29.67, for a total value of $2,730,322.41.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Price Performance

Shares of VOR opened at $26.92 on Wednesday. The company’s 50 day simple moving average is $34.88. The company has a market cap of $184.40 million, a P/E ratio of -0.10 and a beta of 2.07. Vor Biopharma Inc. has a 12-month low of $2.62 and a 12-month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Wall Street Analyst Weigh In

Several equities analysts have weighed in on VOR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Baird R W upgraded Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a report on Wednesday, September 24th. Zacks Research cut Vor Biopharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Finally, Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and raised their price target for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vor Biopharma presently has an average rating of “Hold” and an average target price of $77.83.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ariose Capital Management Ltd purchased a new position in shares of Vor Biopharma in the 3rd quarter worth approximately $5,368,000. XTX Topco Ltd purchased a new position in shares of Vor Biopharma in the 2nd quarter worth approximately $66,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. Jane Street Group LLC purchased a new position in shares of Vor Biopharma in the 1st quarter worth approximately $140,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Vor Biopharma in the 1st quarter worth approximately $100,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.